The highest time to reach end point (TTE), median survival time (MST), increased life span (ILS), and tumor growth delay (TGD) were observed in the Lip-EPA + Lip-gp100 combination therapy group (MST > 28 days, TTE = 34.99 ± 11.89 days, ILS > 47.36%, TGD = 56.54%), which was higher than the other groups (Table 5). This evidence concerns the gene PMEL and neoplasm.